NDAORALTABLET
Approved
Nov 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
AVANDARYL (glimepiride; rosiglitazone maleate) by Teva is cells. Approved for type 2 diabetes mellitus ( ), type 1 diabetes mellitus, type 2 diabetes mellitus. First approved in 2005.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVANDARYL is a fixed-dose combination tablet containing glimepiride (a sulfonylurea) and rosiglitazone maleate (a thiazolidinedione) indicated for type 2 diabetes mellitus. It works through dual mechanisms: glimepiride stimulates insulin release from pancreatic beta cells via ATP-sensitive potassium channel closure, while rosiglitazone enhances insulin sensitivity in peripheral tissues by activating PPARγ nuclear receptors.
LOE Approaching
As a fixed-dose combination approaching loss of exclusivity, AVANDARYL teams are typically in maintenance or wind-down mode with minimal new hiring.
Mechanism of Action
cells. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin.
Indications (3)
Worked on AVANDARYL at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.